Chronic Coronary Syndromes Nowadays

taller de imágenes y fisiología intracoronaria

Multiple drugs and treatment strategies have emerged in recent years to change significantly the prognosis of patients who suffer from stable chronic angina or, in terms of the latest guidelines, “chronic coronary syndromes.” This semantic change may seem of little importance, but it is intended to remind us that these are not stable patients, but patients whose progress presents stable phases and acute phases.

This study analyzed data from 32,703 patients (from 45 countries) with chronic coronary syndromes enrolled in the CLARIFY registry from November 2009 to June 2010, with a 5-year follow-up.

The primary endpoint, cardiovascular death or non-fatal infarction, was 8% for the overall population (male 8.1%; female 7.6%).


Read also: Down with the Myth of Polymer-Free Stents in High Bleeding Risk.


The most important independent predictors of risk were prior hospitalization for heart failure, current smoking, living in Central/South America, prior infarction, prior stroke, diabetes, angina symptoms, and peripheral vascular disease.

There was a strong interaction in patients who had a history of prior infarction and who experienced angina symptoms, compared with patients with a history of infarction who were asymptomatic (11.8% vs. 8.2%, p < 0.001).

Among patients who had never experienced an infarction, the rate of events was similar for those with and without angina (6.3% vs. 6.4%, p > 0.99).


Read also: Is There a “Safe” Dose for Meat Consumption?


The rate of drug prescription based on evidence for secondary prevention was very high.

Conclusion

This registry describes the whole spectrum of patients with stable coronary syndromes and shows that, despite adequate secondary prevention, patients with both angina and prior infarction have high rates of events. This high-risk subgroup is easily identifiable and warrants intensive treatment.

2020-02-27-ehz660abierto

Original Title: Long-term outcomes of chronic coronary syndrome worldwide: insights from the international CLARIFY registry.

Reference: Emmanuel Sorbets et al. European Heart Journal (2020) 41, 347–355.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

ACVC 2026 | CELEBRATE Trial: Prehospital Zalunfiban Use in STEMI

Optimizing antithrombotic therapy in the prehospital phase of ST-segment elevation myocardial infarction (STEMI) remains challenging due to the delayed onset of action of P2Y12...

ACVC 2026 | BOX Substudy: Mean Arterial Pressure Targets in Cardiogenic Shock After OHCA

Hemodynamic management of cardiogenic shock following ischemic out-of-hospital cardiac arrest (OHCA-AMICS) remains an unresolved issue, particularly regarding optimal mean arterial pressure (MAP) targets and...

Drugs for the Treatment of No-Reflow During PCI

The no-reflow phenomenon is one of the most frustrating complications of primary angioplasty (pPCI), reflecting persistent microvascular damage that, in the mid- to long-term,...

Rotational atherectomy and its technical secrets: use of floppy or ES guidewire

Rotational atherectomy (RA) remains a very useful tool in the management of severe coronary calcification. However, many of its technical aspects rely more on...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACVC 2026 | CELEBRATE Trial: Prehospital Zalunfiban Use in STEMI

Optimizing antithrombotic therapy in the prehospital phase of ST-segment elevation myocardial infarction (STEMI) remains challenging due to the delayed onset of action of P2Y12...

ACVC 2026 | BOX Substudy: Mean Arterial Pressure Targets in Cardiogenic Shock After OHCA

Hemodynamic management of cardiogenic shock following ischemic out-of-hospital cardiac arrest (OHCA-AMICS) remains an unresolved issue, particularly regarding optimal mean arterial pressure (MAP) targets and...

ACVC 2026 | FLASH Registry European Cohort: Mechanical Thrombectomy in Pulmonary Embolism

The management of intermediate-high and high-risk pulmonary embolism (PE) remains an area of therapeutic uncertainty, particularly in patients with right ventricular (RV) dysfunction, in...